<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8294">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01993004</url>
  </required_header>
  <id_info>
    <org_study_id>IRB0220060134</org_study_id>
    <nct_id>NCT01993004</nct_id>
  </id_info>
  <brief_title>Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells</brief_title>
  <official_title>Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported
      in many human diseases. The purpose of this pilot study is to determine if microRNA
      expression is changed in untreated and glatiramer acetate-treated patients with multiple
      sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported
      in many human diseases. The purpose of this pilot study is to determine if microRNA
      expression is changed in untreated and glatiramer acetate-treated patients with multiple
      sclerosis. The expression of microRNA will be analysed in cell subsets separated from
      peripheral blood mononuclear cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Relative MicroRNA expression in B cells</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Expression of multiple microRNA is being tested in B cells in three groups of subjects at one time point</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Self-explanatory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated patients</arm_group_label>
    <description>Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treated patients</arm_group_label>
    <description>Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Glatiramer acetate prior to enrollment</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Control human subjects and patients with RRMS will be enrolled in New Brunswick, NJ
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        18-60 year-old healthy subjects or patients with RRMS/CIS

        Exclusion Criteria:

          1. Any treatment with steroids in the last 30 days prior to the blood draw or any
             immunosuppressive or Disease-modifying treatment (DMT) other than Glatiramer Acetate
             in the last 90 days

          2. Presence of other disorders that may be associated with immune-deficient or
             autoimmune process (e.g., HIV, lymphoma, lupus) or demyelinating disease other than
             MS (e.g., Lyme, B12 deficiency)

          3. Pregnancy

          4. Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk
             about 100 meters with or without resting (Expanded Disability Status Scale (EDSS)
             score greater than 5.5)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantin Balashov, MD, PhD, FAAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers-RWJMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konstantin Balashov, MD, PhD, FAAN</last_name>
    <phone>732-235-7727</phone>
    <email>konstantin.balashov@rutgers.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rutgers-RWJMS</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Balashov, MD, PhD, FAAN</last_name>
      <phone>732-235-7727</phone>
      <email>konstantin.balashov@rutgers.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Konstantin Balashov</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Copolymer 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
